Table 1 Baseline characteristics of the study patients (n = 47)
Age, years | 57.0 (50.0, 63.0) |
55.0 (10.1) | |
BMI, kg/m2 | 24.5 (23.1, 29.4) |
25.9 (4.8) | |
Breast cancer | |
 Early-stage | 38 (81) |
 Advanced-stage | 9 (19) |
 Anthracycline-based chemotherapy | 38 (81) |
 Left-sided radiotherapy | 12 (26) |
Cardiovascular risk factors | |
 Hypertension | 17 (36) |
 Diabetes mellitus | 3 (6) |
 Hypercholesterolemia | 7 (15) |
 Positive family history | 15 (32) |
 Current or ever smoker | 13 (28) |
Cardiac condition before treatment | |
 Valve insuffiency | 0 (0) |
 Arrhytmia | 1 (2) |
 MI/CABG/PCI | 0 (0) |
Cardiovascular medication | |
 Beta-blockers | 1 (2) |
 ACE inhibitors | 2 (4) |
 Both | 1 (2) |
CMR imaging parameters | |
 LVEF, % | 60.4 (55.8, 66.0) |
60.6 (7.3) | |
 GLS, % | -18.7 (−20.1, −16.9) |
−18.1 (5.6) | |
 GRS, % | 30.1 (24.5, 32.9) |
29.5 (5.8) | |
 Left ventricular mass, g | 73.6 (65.4, 88.0) |
76.3 (15.2) | |
 Length left ventricle diastolic phase, mm | 86.0 (81.5, 89.5) |
85.9 (6.6) | |
 LGE, % | 6.0 (5.0–8.0) |
6.9 (3.1) | |
2DE parameters | |
 LVEF, % | 66.0 (63.0, 73.0) |
67.5 (6.5) | |
 ST-LVEF, % | 57.2 (53.3, 62.6) |
56.9 (8.1) | |
 ST-GLS, % | −18.8 (− 20.6, −16.3) |
−18.4 (3.0) | |
 ST-GRS, % | 21.4 (13.5, 34.1) |
23.6 (13.1) | |